Open an account

Anixa Biosciences

ANIX · NASDAQ

$2.68+$0.07 (+2.68%)TodayMarket closed ·
Prev close $2.61

About ANIX

Anixa Biosciences, Inc. is a biotechnology company, which engages in the development of therapies and vaccines focused on oncology. The company is headquartered in San Jose, California and currently employs 4 full-time employees. The firm is developing therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics program consists of the development of liraltagene autoleucel (lira-cel), a chimeric endocrine receptor-T cell therapy, which is a novel form of chimeric antigen receptor-T cell (CAR-T) technology, initially focused on treating ovarian cancer, that is being developed of its subsidiary, Certainty Therapeutics, Inc. (Certainty). Its vaccine programs include the development of a vaccine against breast cancer, the development of a vaccine against ovarian cancer, and a vaccine discovery program utilizing the same mechanism of its breast and ovarian cancer vaccines to develop additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon and prostate. The company is also developing a method to vaccinate women against breast cancer, focused on triple-negative breast cancer.

Employees
4
Headquarters
San Jose, California
Listed
Oct 7, 1983
Sector
Health Care
Industry
Biotechnology
Website
anixa.com

ANIX key statistics

Market cap
93.17M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
281.70K
Volume
166.81K
Open price
$2.64
High today
$2.75
Low today
$2.64
52 Week high
$5.46
52 Week low
$2.32

Anixa Biosciences (ANIX) at a glance

As of Oct 20, 2026, Anixa Biosciences (ANIX) shares are priced at $2.68, giving the company a market cap of 93.17M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $2.64 and $2.75. The current price is 1.5% above the day's low and 2.5% below its high.

Volume so far is 166.81K shares, below the average of 281.70K shares a day.

Over the past year Anixa Biosciences has ranged from $2.32 to $5.46, and now sits 11% of the way up that range.

Anixa Biosciences met or beat analyst EPS estimates in 6 of the last 8 quarters. In Q3 FY26 it reported -$0.08 per share against an estimate of -$0.0877.

The average analyst price target is $9.94, 271.1% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 2 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 6 analystsAvg $9.94
Low
$6.06
Now
$2.68
High
$14.70

ANIX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 6 of the last 8 quarters, by 14.2% on average.

  1. Q4 FY24: reported -$0.09 per share against an estimate of -$0.0867
  2. Q1 FY25: reported -$0.10 per share against an estimate of -$0.102
  3. Q2 FY25: reported -$0.09 per share against an estimate of -$0.102
  4. Q3 FY25: reported -$0.07 per share against an estimate of -$0.0918
  5. Q4 FY25: reported -$0.09 per share against an estimate of -$0.0893
  6. Q1 FY26: reported -$0.08 per share against an estimate of -$0.0969
  7. Q2 FY26: reported -$0.07 per share against an estimate of -$0.0893
  8. Q3 FY26: reported -$0.08 per share against an estimate of -$0.0877

ANIX news

  • Press releasePRNewswire

    Anixa Biosciences' Ovarian Cancer CAR-T Therapy Inventor to Deliver Keynote at Ovarian Cancer Midwest Focus Conference

  • Press releasePRNewswire

    Anixa Biosciences Announces First Case of Stable Disease for Three Months in Ovarian Cancer CAR-T Clinical Trial

  • Press releasePRNewswire

    Anixa Biosciences Announces Treatment of Second Patient in the Fifth Cohort of its Ovarian Cancer CAR-T Clinical Trial

  • Press releasePRNewswire

    Anixa Biosciences Granted First Australian Patent for its Breast Cancer Vaccine, Broadening Global Protection Through 2040

  • Press releasePRNewswire

    Anixa Biosciences Appoints UPenn's Dr. Carmen Guerra to Cancer Business Advisory Board

  • Press releasePRNewswire

    Anixa Biosciences Interview Highlighting Breast Cancer Vaccine to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV

  • Press releasePRNewswire

    Anixa Biosciences to Present at the Nasdaq & LD Micro Inaugural SF Summit on September 9, 2026

  • Press releasePRNewswire

    Anixa Biosciences to Present at the 2026 Cantor Fitzgerald Global Healthcare Conference Highlighting its Breast Cancer Vaccine and Ovarian Cancer CAR-T Therapy

Similar companies

Companies in the same industry as Anixa Biosciences

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.